Company news
Vectus Biosystems Limited (ASX:VBS) news
Vectus Biosystems Limited news releases on 6ix. Latest, Sep 29, 2026: FDA Pre-IND Meeting Request Granted for VB0004
Press releases & updates
FDA Pre-IND Meeting Request Granted for VB0004
September 29, 2026
Placement of Shares
May 22, 2026
Appointment of Dr Tara Speranza as CEO & CTO
May 7, 2026
VB4-P5 Renal Compound Transaction Settled
April 13, 2026
Half Year Report & Appendix 4D
February 26, 2026
Quarterly Activities & Appendix 4C Cash Flow Reports
January 30, 2026
Response to ASX Query Letter
November 11, 2025
Reinstatement to Quotation
October 17, 2025
VB4-P5 Renal Compound Transaction
October 17, 2025
Suspension from Quotation
October 17, 2025
Trading Halt
October 15, 2025
Pause in Trading
October 15, 2025
Preliminary Final Report
August 29, 2025
Agreement with C14 Consulting Group
August 30, 2024
Passing of Vectus CEO
May 20, 2024
Quarterly Activities/Appendix 4C Cash Flow Report
October 31, 2023
Preliminary Final Report - Appendix 4E
August 30, 2023
Half Yearly Report & Appendix 4D
February 24, 2023
Issue Of Shares Under Placement
December 1, 2022
Vectus - $3.5 million placement
November 22, 2022
Completion of Phase Ia for VB0004
September 14, 2022
Completion of Second M.A.D. Study for VB0004
August 8, 2022
Quarterly Activities Report & Appendix 4C
July 28, 2022
Completion of Final S.A.D. Study and First M.A.D. Study
May 25, 2022
Half Yearly Report and Appendix 4D
February 25, 2022
A Significant Milestone for VB0004
February 20, 2022
Chairman & CEO Address to Shareholders
January 24, 2022
Third S.A.D. Group Reviewed By Trial Safety Review Committee
November 28, 2021
Response to ASX Price and Volume Query
October 19, 2021
Update on Phase I Human Trial
September 6, 2021
Successful Completion of First Group in Phase I Human Trial
August 23, 2021
Approval Received for Phase I Trial in Australia
June 16, 2021
Vectus completes $7 million placement
November 20, 2020
Proposed issue of Securities - VBS
November 20, 2020
Quarterly Activities Report and Appendix 4C
July 31, 2020
Appendix 4C - Quarterly Report
April 30, 2020
Half Year Report
February 28, 2020
Appendix 4C - quarterly
October 31, 2019
Response to ASX Price Query
September 24, 2019
Convertible Note Issue
September 17, 2019
Preliminary Final Report Appendix 4E
August 30, 2019
Response to Appendix 4C Query
August 9, 2019
Half Year Report and Appendix 4D
February 28, 2019
Response to ASX Appendix 4C Query
February 22, 2019
CEOs Address to Shareholders
November 14, 2018
Chairmans Address to Shareholders
November 14, 2018
Appendix 4C - Quarterly
October 31, 2017
Successful Pre-Clinical Trial and Granting of Key Patent
October 20, 2017
Appendix 4C - Quarterly Report and Update
April 28, 2017
Admission to Official List
March 30, 2016